论文部分内容阅读
目的了解2004-2006年长江流域6城市脑血管循环药物应用状况。方法对6城市入网医院2004-2006年临床应用的脑血管循环药物的数据资料进行统计分析,从用药金额和用药频度(DDDs)进行排序。结果长江流域6城市脑血管循环药物的用药总金额2005年和2006年分别较上一年增长了19.13%、16.55%,总用药频度2005年较上一年增长了42.16%,而2006年比2005年下降了18.76%。在6城市3 a总用药频度排序中始终位于前3位的药物是脑蛋白水解物、阿米三嗪-萝巴新、氟桂利嗪,3 a总用药金额排序中始终位于前3位的是阿米三嗪-萝巴新、小牛血去蛋白提取物、脑蛋白水解物。结论长江流域6城市脑血管循环药物3 a内占主导的药物变化不大,且各城市占主导的脑血管循环药物也相似,但也有一些药物其金额排序与DDDs排序相差很大的,所以在面对种类繁多的脑血管循环药物时,临床医生需要考虑如何合理使用的问题。
Objective To understand the application of cerebrovascular circulation drugs in 6 cities in the Yangtze River valley from 2004 to 2006. Methods The data of cerebral circulation drugs in clinical application from 2004 to 2006 in 6 city hospitals were statistically analyzed, and the data were sorted according to the amount of medication and frequency of DDDs. Results The total amount of medication for cerebrovascular recirculation in 6 cities in the Yangtze River valley increased by 19.13% and 16.55% respectively over the previous year in 2005 and 2006, with the frequency of total medication increasing by 42.16% in 2005 over the previous year. In 2006, In 2005 decreased by 18.76%. In the 6 cities in the 3 a frequency of medication always ranked in the top three drugs are brain protein hydrolyzate, amilotriazine - carvedilol, flunarizine, 3 a total medication amount always ranked in the top 3 Ami triazine - radapus, bovine blood protein extract, brain protein hydrolyzate. Conclusion Six cities in the Yangtze River Basin, cerebral vascular drugs within 3 a dominated drugs changed little, and the city dominated cerebral vascular drugs are similar, but there are also some drugs in the amount of sorts and DDDs sort of very different, so in Faced with a wide range of cerebral vascular drugs, clinicians need to consider how to use them properly.